Summary
With regard to progression to diabetes, ICA cross-reactive with mouse pancreas, antibodies to the Mr 64,000 islet antigen (64K), antibodies immunotrap-ping brain GAD activity, and IAA were analysed in 53 ICA-positive first-degree relatives of IDDM patients and 18 ICA-positive schoolchildren without a family history of diabetes. Sera from 29 (55 %) relatives did not bind to mouse pancreas, whereas 24 (45 %) displayed cross-species reaction. ICA titres on human and mouse pancreas were weakly correlated in the overall population (p >0.05) but more strongly (p >0.01) in only those subjects who displayed antibodies on tissues from both species. GAD and 64K antibodies were detected in 31 % and 35 % of relatives. In schoolchildren, the frequencies of cross-species reactive ICA (22%), GAD antibodies (6%), 64K antibodies (22%), and IAA (6%), were lower (p > 0.05) than in relatives. A strong correlation (p > 0.0001) was observed between GAD and 64K antibodies. GAD or 64K antibodies were strongly correlated with ICA on human pancreas (p > 0.0001) but poorly with ICA on mouse pancreas (p = 0.05). After pre-incubation of sera with brain ho-mogenate, ICA titres were unaffected on mouse pancreas but reduced on human pancreas. ICA-positive subjects who displayed neither cross-species reactive ICA nor GAD or 64K antibodies were more frequent (p > 0.05) among schoolchildren than relatives, whereas subjects who displayed all antibody specificities were more numerous (p > 0.04) in relatives. All relatives with ICA binding only to human pancreas, as well as all schoolchildren, permanently displayed an AIRG higher than the first control percentile and remained non-diabetic. Five of ten relatives with cross-species reactive ICA, GAD and 64K antibodies at the same time displayed acute insulin response to glucose which fell below the first control percentile and developed the disease. The cross-species heterogeneity of ICA was thus confirmed in a large series of relatives and revealed in the general population. Detection of cross-species reactive ICA, GAD antibodies, or 64K antibodies enhances the prognostic significance after conventional ICA screening. The combination of these antibodies is more indicative of diabetes development than any antibody alone. Correlations between tests and absorption experiments indicate that GAD 64 is an ICA antigen on human but not on mouse pancreas, and that ICA which recognize GAD 64K coexist with others which react with mouse pancreas but not with GAD. A third ICA subset might have been revealed by high-titred ICA without either cross-species reactivity or GAD or 64K antibodies. This latter state was more frequent in the general population than in relatives and might typify an early immune response which may or may not progress.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- IDDM:
-
insulin-dependent diabetes mellitus
- ICA:
-
islet cell antibodies
- GAD:
-
glutamic acid decarboxylase
- AIRG:
-
acute insulin response to glucose
- JDF:
-
Juvenile Diabetes Foundation
- IAA:
-
insulin autoantibodies
- 64K:
-
Mr 64,000 islet antigen
- IRI:
-
immuno-reactive insulin
References
Bonifacio E, Bingley PJ, Shattock M et al. (1990) Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 335: 147–149
Tarn AC, Thomas JM, Dean BM et al. (1988) Predicting insulin-dependent diabetes. Lancet 1: 845–850
Riley WJ, Maclaren NK, Krischer J et al. (1990) A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N Engl J Med 323: 1167–1172
Bosi E, Becker F, Bonifacio E et al. (1991) Progression to type 1 diabetes in autoimmune endocrine patients with islet cell antibodies. Diabetes 40: 977–984
Landin-Olsson M, Karlsson A, Dahlquist G, Blom L, Lern-mark A, Sundkvist G (1989) Islet cell and other organ-specific autoantibodies in all children developing type 1 (insulin-dependent) diabetes mellitus in Sweden during one year and in matched control children. Diabetologia 32: 387–395
Bruining GJ, Molenaar JL, Grobbe DE et al. (1989) Ten-year follow-up study of islet-cell antibodies and childhood diabetes mellitus. Lancet I: 1100–1103
Bergua M, Sole J, Marion G et al. (1987) Prevalence of islet cell antibodies, insulin antibodies and hyperglycaemia in 2291 schoolchildren. Diabetologia 30: 724–726
Levy-Marchal C, Tichet J, Fajardy I, Gu XF, Dubois F, Czer-nichow P (1992) Islet cell antibodies in normal French schoolchildren. Diabetologia 35: 577–582
Karjalainen JK (1990) Islet cell antibodies as predictive markers for IDDM in children with high background incidence of disease. Diabetes 39: 1144–1150
Bingley PJ, Bonifacio E, Shattock M et al. (1993) Can islet cell antibodies predict IDDM in the general population? Diabetes Care 16: 45–50
Bloom A, Hayes TM, Gamble DR (1975) Register of recent-onset diabetic children. BMJ ii: 580–583
Dahlquist G, Blom L, Holmgren Getal. (1985) The epidemiology of diabetes in Swedish children 0-14 years: a six-year prospective study. Diabetologia 28: 802–808
Genovese S, Bonifacio E, McNally JM et al. (1992) Distinct cytoplasmic islet cell antibodies with different risks for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 35: 385–388
Timsit J, Caillat-Zucman S, Blondel H, Chedin P, Bach JF, Boitard C (1992) Islet cell antibody heterogeneity among type 1 (insulin-dependent) diabetic patients. Diabetologia 35: 792–795
Gianani R, Pugliese A, Bonner-Weir S et al. (1992) Prognos-tically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type 1 diabetes. Diabetes 41: 347–353
Sai’ P, Elmansour A, Audrain M, Charbonnel B, Bardet S (1993) Quantification of human cytoplasmic islet-cell antibodies which cross-react with mouse pancreas: a follow-up study in type 1 (insulin-dependent) diabetic patients and in first-degree relatives. Diabetologia 36: 778–784
Baekkeskov S, Landin M, Kristensen JK et al. (1987) Antibodies to a 64,000 Mr human islet cell protein precede the clinical onset of insulin-dependent diabetes. J Clin Invest 79: 926–934
Baekkeskov S, Aanstoot HJ, Christgau S et al. (1990) Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347: 151–156
Seißler J, Hering B, Richter W et al. (1992) Antibodies to the Mr 64,000 (64K) protein in islet cell antibody positive non-diabetic individuals indicate high risk for impaired beta-cell function. Diabetologia 35: 550–554
Atkinson MA, McLaren NK, Scharp DW, Lacy PE, Riley WJ (1990) 64,000 Mr autoantibodies as predictor of insulin-dependent diabetes. Lancet 1: 1357–1360
Barmeier H, McCulloch DK, Neifing JL et al. (1991) Risk for developing type 1 (insulin-dependent) diabetes mellitus and the presence of islet 64K antibodies. Diabetologia 34: 727–733
Christie M, Landin-Olsson M, Sundkvist G, Dahlquist G, Lernmark A, Baekkeskov S (1988) Antibodies to a Mr-64000 islet cell protein in Swedish children with newly diagnosed type 1 (insulin-dependent) diabetes. Diabetologia 31: 597–602
Velloso LA, Kämpe O, Hallberg A, Christmanson L, Bets-holtz C, Karlsson FA (1993) Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest 91: 2084–2090
Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ (1992) Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 89: 283–292
Christie MR, Vohra G, Champagne P, Daneman D, Delo-vitch TL (1990) Distinct antibody specificities to a 64-kD islet cell antigen in type 1 diabetes as revealed by trypsin treatment. J Exp Med 172: 789–794
Christie MR, Brown TJ, Cassidy D (1992) Binding of antibodies in sera from type 1 (insulin-dependent) diabetic patients to glutamate decarboxylase from rat tissues. Evidence for antigenic and non-antigenic forms of the enzyme. Diabetologia 35: 380–384
Thivolet CH, Tappaz M, Durand A et al. (1992) Glutamic acid decarboxylase (GAD) autoantibodies are additional predictive markers of type 1 (insulin-dependent) diabetes mellitus in high risk individuals. Diabetologia 35: 570–576
Christie MR, Tun RYM, Lo SSS et al. (1992) Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Studies with identical twins. Diabetes 41: 782–787
Christgau S, Schlerbeck H, Aanstoot HK et al. (1991) Pancreatic β cells express two autoantigenic forms of glutamic acid decarboxylase, a 65 kDa hydrophilic form and a 64-kDa amphiphilic form which can be both membrane-bound and soluble. J Biol Chem 266: 21257–21264
Karlsen AE, Hagopian WA, Petersen JS et al. (1992) Recom-binant glutamic acid decarboxylase (representing the single isoform expressed in human islets) detects IDDM-associated 64,000-Mr autoantibodies. Diabetes 41: 1355–1359
Velloso LA, Kampe O, Eizirik DL, Hallberg A, Andersson A, Karlsson FA (1993) Human autoantibodies react with glutamic acid decarboxylase antigen in human and rat but not in mouse pancreatic islets. Diabetologia 36: 39–46
Petersen JS, Russel S, Marshall MO et al. (1993) Differential expression of glutamic acid decarboxylase in rat and human islets. Diabetes 42: 484–495
Atkinson MA, Kaufman DL, Newman D, Tobin AJ, Mclaren NK (1993) Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J Clin Invest 91: 350–356
Colman PG, Nayak RC, Campbell IL, Eisenbarth GS (1988) Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid extracts. Diabetes 37: 645–652
Dotta F, Peterson LB, Previti M et al. (1992) Pancreatic islet ganglioside expression in NOD mice: comparison with C57BL/10 mice and changes after autoimmune β-cell destruction. Endocrinology 130: 37–42
Bottazzo GF, Florin-Christensen A, Doniach D (1974) Isletcell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet II: 1279–1283
Bonifacio E, Lernmark A, Dawkins RL et al. (1988) Serum exchange and the use of dilutions have improved precision of measurement of islet cell antibodies. J Immunol Methods 106:83–88
Kuglin B, Kolb H, Greenbaum C, Maclaren NK, Lernmark A, Palmer JP (1990) The fourth international workshop on the standardisation of insulin autoantibody measurement. Diabetologia 33:638–639
Palmer JP, Asplin CM, demons P et al. (1983) Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222:1337–1339
Bardet S, Rohmer V, Maugendre D et al. (1991) Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34: 648–654
Bardet S, Pasqual C, Maugendre D, Remy JP, Charbonnel B, Sa’i P (1989) Inter- and intra-individual variability of acute insulin response during intravenous glucose tolerance tests. Diabete Metab 15:224–232
Bardet S, Joseph MG, Maugendre D et al. (1993) Predictive value of age-related acute insulin response to glucose in sub- jects at risk for type 1 diabetes: results of a 6-year follow-up study from West-France. Diabete Metab 39:372–380
Vardi P, Dib SA, Tuttleman M et al. (1987) Competitive insulin autoantibody assay. Prospective evaluation of subjects at high risk for development of type 1 diabetes mellitus. Diabetes 36:1286–1291
Dean BM, Becker F, McNally JM et al. (1986) Insulin autoantibodies in the pre-diabetic period: correlation with islet cell antibodies and development of diabetes. Diabetologia 29:339–342
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chaillous, L., Elmansour, A., Charbonnel, B. et al. Combined analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the Mr 64,000 islet protein, and antibodies to glutamate decarboxylase in subjects at risk for IDDM. Diabetologia 37, 491–499 (1994). https://doi.org/10.1007/s001250050137
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/s001250050137